Showing results (101-110 of 123) with videos related to
Sort By:
Pageof 13
The Lancet. HIV|February 5, 2022
A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trialRoland Landman, Pierre de Truchis, Lambert Assoumou, et al.Plos Pathogens|April 19, 2021
Mechanisms of HIV-1 evasion to the antiviral activity of chemokine CXCL12 indicate potential links with pathogenesisMarie Armani-Tourret, Zhicheng Zhou, Romain Gasser, et al.AIDS (London, England)|September 12, 2025
No evidence of an effect of the M184I/V on the doravirine/lamivudine/tenofovir switch efficacy in people with HIVCathia Soulié, Aliou Baldé, Djeneba Fofana, et al.The Journal of Antimicrobial Chemotherapy|June 17, 2024
DORAVIR: a French national survey of people with HIV-1 treated with an antiretroviral regimen including doravirineCathia Soulie, Aliou Balde, Djeneba Fofana, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|December 21, 2018
Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM StudyMaud Lemoine, Lambert Assoumou, Stephane De Wit, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 19, 2023
Incidence of Hypertension and Blood Pressure Changes in Persons With Human Immunodeficiency Virus at High Risk for Cardiovascular Disease Switching From Boosted Protease Inhibitors to Dolutegravir: A Post-hoc Analysis of the 96-week Randomised NEAT-022 TrialAbiu Sempere, Lambert Assoumou, Ana González-Cordón, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 19, 2022
Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized TrialLaura Waters, Lambert Assoumou, Ana González-Cordón, et al.HIV Medicine|January 7, 2026
Effectiveness and safety of two-drug regimens containing an integrase inhibitor and reverse transcriptase inhibitor in a cohort of virologically suppressed people with HIV: Data from the COMBINE-2 studyCristina Mussini, Cassidy Henegar, Lambert Assoumou, et al.Sexually Transmitted Infections|April 18, 2025
Acceptability of public health information and prevention measures by gay men, bisexual men and men who have sex with men during the French Mpox outbreak in 2022: the ANRS-MPX-SHS cross-sectional surveyLuis Sagaon-Teyssier, Maxime Hoyer, Marie Dos Santos, et al.Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|May 16, 2019
Piloting a surveillance system for HIV drug resistance in the European UnionMarita Jw van de Laar, Arnold Bosman, Anastasia Pharris, et al.Pageof 13